Search Result

Results for "

Seizures

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (2) 5-HT Receptor (8) Acyltransferase (1) Adenosine Kinase (2) Adenosine Receptor (7) Adenylate Cyclase (3) Adrenergic Receptor (1) Akt (2) Amino Acid Decarboxylase (1) Amino Acid Derivatives (1) AMPK (2) Androgen Receptor (1) Antibiotic (2) AP-1 (1) Apoptosis (19) Autophagy (12) Bacterial (8) Bcl-2 Family (1) Beta-secretase (4) Biochemical Assay Reagents (1) Calcium Channel (11) Carbonic Anhydrase (10) Caspase (9) Cholinesterase (ChE) (1) COX (1) Cuproptosis (2) Cyclic GMP-AMP Synthase (2) Cytochrome P450 (1) Dopamine Receptor (2) Drug Derivative (7) Drug Intermediate (2) Drug Isomer (1) Drug Metabolite (13) Dynamin (1) EAAT (2) EGFR (3) Endogenous Metabolite (14) Endothelin Receptor (1) Environmental Pollutants (1) ERK (2) Ferroptosis (2) Fungal (1) G protein-coupled Bile Acid Receptor 1 (1) GABA Receptor (35) GLUT (1) Glutaminase (1) Glycine Receptor (GlyR) (1) GlyT (3) GSK-3 (1) Histamine Receptor (11) iGluR (20) Interleukin Related (1) Isotope-Labeled Compounds (18) Keap1-Nrf2 (2) mAChR (5) MAGL (1) mGluR (4) Mitochondrial Metabolism (3) mTOR (2) Neurokinin Receptor (1) Neuropeptide Y Receptor (2) NKCC (4) NO Synthase (1) Opioid Receptor (5) P-glycoprotein (3) p38 MAPK (4) PARP (4) Phosphatase (1) PI3K (2) PKA (1) Potassium Channel (11) Ras (1) Reactive Oxygen Species (ROS) (6) Reference Standards (34) ROCK (2) Sex Pheromone (1) Sigma Receptor (1) Sodium Channel (30) Somatostatin Receptor (3) STING (2) TNF Receptor (1) TRP Channel (3) TSPO (1) VEGFR (2)
By Research Areas:	Cancer (38) Cardiovascular Disease (28) Endocrinology (2) Infection (12) Inflammation/Immunology (24) Metabolic Disease (23) Neurological Disease (214)
Oligonucleotides:	Nucleoside Analogs (1) Antisense Oligonucleotides (2)

234

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2309

Kainic acid 30+ Cited Publications	EAAT	Neurological Disease
Kainic acid is a potent excitotoxic agent. Kainic acid hydrate also is an agonist for a subtype of ionotropic glutamate receptor. Kainic acid induces seizures .

HY-B1692

L-Methionine-DL-sulfoximine 5+ Cited Publications MSX; MSO	Glutaminase	Neurological Disease
L-Methionine-DL-sulfoximine (MSX; MSO), a highly specific and irreversible inhibitor of Glutamine synthetase (GS), is also a potent convulsant which metabolically and morphologically primarily affects astroglia. L-Methionine-DL-sulfoximine has been employed to inhibit the Gln-dependent ammonia-stimulated neuronal toxicity in vitro, potentiating Gln deficit-dependent depression. L-Methionine-DL-sulfoximine tremendously increases the rate of release of fixed nitrogen in cyanobacteria. L-Methionine-DL-sulfoximine is a promising candidate for research in biofertilizers and convulsive seizures (CS) .

HY-B0495

Lamotrigine 5+ Cited Publications LTG; BW430C	Sodium Channel Autophagy	Neurological Disease Cancer
Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na ⁺ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .

HY-B0300

Penicillamine 3 Publications Verification D-(-)-Penicillamine	Cuproptosis Drug Metabolite	Inflammation/Immunology Cancer
Penicillamine (D-(-)-Penicillamine) is a penicillin metabolic degradation product, can be used as a heavy metal chelator. Penicillamine increases free copper and increases oxidative stress. Penicillamine has effect of seizures through nitric oxide/NMDA pathways. Penicillamine is a potential immune modulator. Penicillamine can be used for the research of Wilson disease, rheumatoid arthritis, and cystinuria .

HY-W010155

Tryptophol 2 Publications Verification Indole-3-ethanol	Endogenous Metabolite Apoptosis Caspase Bacterial	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Tryptophol is an aromatic alcohol and secondary metabolite produced by microorganisms. Tryptophol induces apoptosis and cleavage of caspase-8. Tryptophol inhibits *Cunninghamella blakesleeana* biofilm. Tryptophol has anti-phage infection, biofilm formation regulation, anti-inflammatory, hemolytic, sleep induction, temperature change, seizure susceptibility and immune regulation activities. Tryptophol is used in the research of African trypanosomiasis, sleep disorders, epilepsy .

HY-N2522

Carboxyatractyloside dipotassium 2 Publications Verification Gummiferin dipotassium	Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS)	Neurological Disease
Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca ²⁺ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .

HY-N1502

Carboxyatractyloside tripotassium 2 Publications Verification Gummiferin tripotassium	Mitochondrial Metabolism Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
Carboxyatractyloside tripotassium is a diterpenoid. Carboxyatractyloside tripotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside tripotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside tripotassium promotes ROS production, induces Ca ²⁺ release, and leads to mitochondrial dysfunction. Carboxyatractyloside tripotassium induces lethargy, weakness, and epileptic seizures in rats .

HY-B0124

Zonisamide 3 Publications Verification AD 810; CI 912	Carbonic Anhydrase Apoptosis	Neurological Disease
Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-B1302

Quinidine hydrochloride monohydrate 20+ Cited Publications	P-glycoprotein PARP Caspase Apoptosis Potassium Channel	Cardiovascular Disease Neurological Disease
Quinidine hydrochloride monohydrate is an orally active antiarrhythmic agent. Quinidine hydrochloride monohydrate reduces the expression level of P-gp, inhibits P-gp-mediated efflux, increases the intracellular accumulation of P-gp substrates, induces PARP cleavage and Caspase-3 activation, and elevates the proportion of Apoptotic cells at the sub-G1 phase. Quinidine hydrochloride monohydrate exerts sustained block and open-channel block effects on I_K(f). Quinidine hydrochloride monohydrate alters the urinary metabolic ratio of Amphetamine, modulates the Pentylenetetrazol-induced seizure threshold, and regulates the anticonvulsant effect of Dextromethorphan. Quinidine hydrochloride monohydrate can be used in studies related to uterine sarcoma and seizures .

HY-103181

N6-Cyclopentyladenosine CPA; UK-80882	Adenosine Receptor Apoptosis	Cardiovascular Disease Neurological Disease Cancer
N6-Cyclopentyladenosine (CPA) is a selective Adenosine A₁ receptor agonist, with K_i values of 2.3 nM, 790 nM and 43 nM for human A₁, A_2A and A₃ receptors, respectively. N6-cyclopentyladenosine increases Apoptosis. N6-Cyclopentyladenosine has antitumor activity against leukemia. N6-cyclopentyladenosine improves 5-fluorouracil (HY-90006)-induced hematopoietic damage, regulates sleep, and delays Aminophylline-induced clonic epileptic seizures .

HY-172431

Opakalim BHV-7000	Potassium Channel	Neurological Disease
Opakalim (BHV-7000) is a selective Kv7.2/7.3 potassium channels activator with an EC₅₀ of 0.6 μM. Opakalim shows minimal GABAA receptor activation and exhibits potent anti-seizure efficacy in the maximal electroshock seizure (MES) model. Opakalim can be used for the study of seizures .

HY-A0092

Trimethadione 3,5,5,-Trimethyloxazolidine-2,4-dione	Calcium Channel	Neurological Disease
Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects .

HY-118424

JNJ-55511118	iGluR	Neurological Disease Metabolic Disease
JNJ-55511118 is a selective TARP γ-8 binding AMPA receptor modulator with oral bioavailability and blood-brain barrier permeability, with a K_i of 26 nM. JNJ-55511118 reduces voluntary intake of sweetened alcohol in male mice. In rodent models, JNJ-55511118 inhibits hippocampal neurotransmission, reduces specific electroencephalogram frequency bands, induces transient hyperlocomotion, impairs learning and memory abilities, and exerts anticonvulsant effects. JNJ-55511118 is applicable to research related to alcohol use disorder and seizures .

HY-114703

Eslicarbazepine 1 Publications Verification BIA 2-194	Beta-secretase Sodium Channel	Neurological Disease
Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.

HY-N2309A

Kainic acid hydrate 30+ Cited Publications	mGluR	Neurological Disease
Kainic acid hydrate is a potent excitotoxic agent. Kainic acid hydrate also is an agonist for a subtype of ionotropic glutamate receptor. Kainic acid hydrate induces seizures .

HY-153068

CZL55	Caspase	Neurological Disease
CZL55 is a caspase-1 inhibitor. CZL55 can be used for the research of febrile seizures (FS) .

HY-W008270

2(5H)-Furanone γ-Crotonolactone	Endogenous Metabolite Bacterial	Infection Neurological Disease
2(5H)-Furanone (γ-Crotonolactone) is an endogenous metabolite. 2(5H)-Furanone mimics N-acyl homoserine lactone signals, occupies the binding site of LuxR homologs, and interferes with quorum sensing-mediated gene regulation. 2(5H)-Furanone inhibits quorum sensing mediated by AHLs with different acyl chain lengths. 2(5H)-Furanone inhibits biofilm formation of environmental Aeromonas hydrophila strains on polystyrene plates. 2(5H)-Furanone suppresses spike-and-wave discharges in a rat model of generalized absence seizures and exhibits selective activity against absence seizures. 2(5H)-Furanone can be used in studies related to bacteria infections and generalized absence seizures.

HY-Y0378

D-Leucine (R)-Leucine	Endogenous Metabolite	Neurological Disease
D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-103185

CCPA 1 Publications Verification 2-Chloro-N6-cyclopentyladenosine	Adenosine Receptor Adenylate Cyclase	Cardiovascular Disease Neurological Disease
CCPA (2-Chloro-N6-cyclopentyladenosine) a highly selective A1 adenosine receptors agonist with a K_i of 0.4 nM. CCPA inhibits adenylate cyclase with an IC₅₀ of 33 nM. CCPA exhibits anti-seizure and cardiacprotective activity. CCPA can be used for the research of seizure and myocardial infarction .

HY-122489

DL-Laudanosine	Drug Metabolite	Neurological Disease
DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity .

HY-138668

JW-65	TRP Channel	Neurological Disease
JW-65 is a selective TRPC3 channel inhibitor with favorable blood-brain barrier penetration. JW-65 directly binds to human TRPC3 protein and modulates calcium signaling to reduce seizure susceptibility. JW-65 reduces seizure incidence, severity, and duration while prolonging seizure latency in multiple seizure models. JW-65 alleviates Aβ‑induced neuronal damage. JW-65 serves as a valuable tool for research on epilepsy, seizure disorders, and Alzheimer’s disease .

HY-118467

Benzolamide 2 Publications Verification CL11366	Carbonic Anhydrase	Neurological Disease Cancer
Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with K_is of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a K_i of 54 nM. Benzolamide can be used for the research of glaucoma and seizures .

HY-B1730

Phensuximide 2 Publications Verification	Cyclic GMP-AMP Synthase	Neurological Disease Metabolic Disease
Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal .

HY-148327

AK-IN-1	Adenosine Kinase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
AK-IN-1 (compound 4072-2732) is an adenosine kinase (AK) inhibitor that is competitive for adenosine (Ado) but not for ATP. AK-IN-1 inhibits 86%, 87% and 89% of AK activity at concentrations of 2, 4 and 10 µM, respectively. AK-IN-1 has good potential for research in many disease areas, including ischaemia, inflammation and seizures .

HY-108497

L-803087	Somatostatin Receptor	Neurological Disease Cancer
L-803087 is a potent and selective somatostatin sst4 receptor agonist with a K_i of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .

HY-12503

CFM-2 1 Publications Verification	iGluR	Neurological Disease Cancer
CFM-2 is a potent and selective non-competitive AMPAR antagonist . CFM-2 possesses anticonvulsant activity in various models of seizures .

HY-123671

CYM2503	Neuropeptide Y Receptor	Neurological Disease
CYM2503 is a putative GalR2-positive allosteric modulator. CYM2503 increases the latency to first electrographic seizure and decreases the total time in seizure. CYM2503 also attenuates electroshock-induced seizures in mice. Galanin receptors type 1 (GalR1) and/or type 2 (GalR2) represent unique pharmacological targets for the research of seizures and epilepsy .

HY-111177

Pheneturide Ethylphenacemide; M 551	Drug Metabolite	Neurological Disease
Pheneturide (Ethylphenacemide, M 551), a decarboxylation product of Phenobarbital, can be used to prevent psychomotor seizures .

HY-179215

OV329 hydrochloride	GABA Receptor	Neurological Disease
OV329 hydrochloride is a potent GABA aminotransferase inactivator. OV329 hydrochloride is a Vigabatrin (HY-15399) analogue. OV329 hydrochloride can increase brain GABA levels and block abnormal intracerebral hyperexcitability. OV329 hydrochloride exhibits anticonvulsant and antiepileptic activities. OV329 hydrochloride can be used for the research of neurological disease, such as seizure .

HY-179215A

OV329	GABA Receptor	Neurological Disease
OV329 is a potent GABA aminotransferase inactivator. OV329 is a Vigabatrin (HY-15399) analogue. OV329 can increase brain GABA levels and block abnormal intracerebral hyperexcitability. OV329 exhibits anticonvulsant and antiepileptic activities. OV329 can be used for the research of neurological disease, such as seizure .

HY-B0495R

Lamotrigine (Standard) 5+ Cited Publications LTG (Standard); BW430C (Standard)	Reference Standards Sodium Channel	Neurological Disease
Lamotrigine (Standard) is the analytical standard of Lamotrigine. This product is intended for research and analytical applications. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na ⁺ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .

HY-Y0378S

D-Leucine-d10 (R)-Leucine-d₁₀	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease
D-Leucine-d₁₀ is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-131204

CZL80	Caspase	Neurological Disease
CZL80, a brain-penetrable caspase-1 inhibitor with an IC₅₀ of 0.01 μM, could be used in the study of febrile seizures and later enhanced epileptogenic susceptibility .

HY-W127668

Triethylcholine iodide	Acyltransferase	Neurological Disease
Triethylcholine iodide is a choline acetyltransferase inhibitor and a regulator of the acetylcholine synthesis pathway. Triethylcholine iodide inhibits acetylcholine synthesis in brain tissues and blocks neuromuscular and autonomic ganglionic transmission. Triethylcholine iodide exerts weak curare-like effects at extremely high concentrations. Triethylcholine iodide elevates the pentylenetetrazol seizure threshold, alters electroencephalogram patterns in Felis catus, but does not affect the maximal electroshock seizure threshold in Oryctolagus cuniculus. Triethylcholine iodide can be used in seizure-related research .

HY-107328

Carumonam disodium	Antibiotic Bacterial	Infection Neurological Disease
Carumonam disodium is a potent antibiotic. Carumonam disodium shows antibacterial activity. Carumonam disodium induces seizure .

HY-P2707

α-Dendrotoxin α-DTX	Sodium Channel Potassium Channel	Neurological Disease
α-Dendrotoxin (α-DTX) is a voltage-gated K ⁺ channel blocker and an acid-sensing ion channel (ASIC) inhibitor. α-Dendrotoxin blocks K_v1.1, K_v1.2, K_v1.6 and D-type (I_D) voltage-gated K ⁺ channels, and reversibly inhibits slowly inactivating potassium currents. α-Dendrotoxin induces epilepsy-related behaviors in mice. α-Dendrotoxin can be used in studies related to tonic-clonic seizures .

HY-106316

CGS 20625	GABA Receptor	Neurological Disease
CGS 20625 is a potent, selective and orally active partial agonist for the central benzodiazepine receptor. CGS 20625 inhibits [3H]-flunitrazepam binding to central benzodiazepine receptors with an IC₅₀ of 1.3 nM. CGS 20625 enhances GABA in Xenopus laevis oocytes . CGS 20625 can be used for the research of pentylenetetrazol-induced seizures and anxiety .

HY-B0124A

Zonisamide sodium AD 810 sodium; CI 912 sodium	Carbonic Anhydrase Apoptosis	Cardiovascular Disease Neurological Disease
Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-101233

ICI 154129 M 154129	Opioid Receptor	Neurological Disease
ICI 154 129 is a delta-opioid receptor antagonist and can be used for seizure research.

HY-114703S1

Eslicarbazepine-d4 BIA 2-194-d₄	Isotope-Labeled Compounds Sodium Channel Beta-secretase	Neurological Disease
Eslicarbazepine-d₄ (BIA 2-194-d₄) is deuterium labeled Eslicarbazepine. Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.

HY-172531

Sulfonadyn-47	Dynamin Ras	Neurological Disease
Sulfonadyn-47 is a GTP-competitive dynamin I (dynI) inhibitor that targets the active site in the GTPase domain of dynamin I, with IC₅₀ values of 3.5 μM against dynI, 27.3 μM in clathrin-mediated endocytosis (CME) assays, and 12.3 μM in synaptic vesicle endocytosis (SVE) assays. Sulfonadyn-47 increases seizure threshold. Sulfonadyn-47 can be used the study for the seizure.

HY-W751152

α,β-Thujone	GABA Receptor	Cancer
α,β-Thujone is a component of the essential oils of some plants. α,β-Thujone causes cancers in male rats and induces seizures in the highest doses .

HY-130325

α-Guanidinoglutaric acid	NO Synthase	Neurological Disease
α-Guanidinoglutaric acid is a guanidino compound first found in cobaltinduced epileptogenic focus tissue in the cerebral cortex of cats. α-Guanidinoglutaric acid induces epileptic seizures in rats after intraventricular administration .

HY-177573

Cholesteryl γ-aminobutyrate	GABA Receptor	Neurological Disease
Cholesteryl γ-aminobutyrate is a γ-aminobutyric acid (GABA)-mimetic prodrug. Cholesteryl γ-aminobutyrate inhibits the orthodromically-evoked discharge of pyramidal cells in the CA1 region of the hippocampus. Cholesteryl γ-aminobutyrate suppresses the open-field activity of mice and rats in a dose-dependent manner and inhibits Bicuculline (HY-N0219)-induced seizures in mice. Cholesteryl γ-aminobutyrate can be used for the study of CNS diseases related to impaired GABAergic neuronal function .

HY-108920

4-Chlorokynurenine 4-Cl-KYN; AV-101	iGluR	Neurological Disease
4-Chlorokynurenine (4-Cl-KYN) is a prodrug of 7-Chlorokynurenic acid (NMDA receptor antagonist) (HY-100811). 4-Chlorokynurenine has orally activity and blood-brain permeability. 4-Chlorokynurenine can reduce depressive symptoms and neurotoxicity. 4-Chlorokynurenine can be used for the research of neurological disease, such as depression and seizure .

HY-12596

JNJ-26489112	Calcium Channel Sodium Channel Potassium Channel	Neurological Disease
JNJ-26489112, a CNS-active agent, exhibits broad-spectrum anticonvulsant activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures. JNJ-26489112 inhibits voltage-gated Na ⁺ channels and N-type Ca ²⁺ channels, and is effective as a K ⁺ channel opener. JNJ-26489112 has very weak inhibition of CA-II (IC₅₀=35 μM) and CA-I (18 μM) .

HY-105365

PD 175069	Calcium Channel	Neurological Disease
PD 175069 is a potent and selective N-type calcium channel antagonist with an IC₅₀ of 0.32 μM. PD 175069 is efficacious in an audiogenic seizure model using DBA/2 mice. PD 175069 can be used for research on neurological conditions such as neuropathic pain and stroke .

HY-178362

CAII/VII-IN-1	Carbonic Anhydrase NKCC mTOR	Neurological Disease
CAII/VII-IN-1 is an orally active hCA II (K_I = 12.3 nM), and hCA VII (K_I = 22.6 nM) inhibitor, showing no significant activity against hCA I. CAII/VII-IN-1 shows excellent neuroprotective activity in vivo Pilocarpine (HY-B0726A)-induced seizure model. CAII/VII-IN-1 can upregulate KCC2 and inhibit mTOR, exerting neuroprotective effects. CAII/VII-IN-1 does not show any significant neurotoxic effects or alterations in liver and kidney function. CAII/VII-IN-1 can be used for the study of epilepsy .

HY-119170

BMS-779333	Androgen Receptor	Neurological Disease Cancer
BMS-779333 is an orally active androgen receptor (AR) antagonist. BMS-779333 is promising for research of prostate cancer and seizure .

HY-100922

N-Acetylglycyl-D-glutamic acid	iGluR	Neurological Disease
N-Acetylglycyl-D-glutamic acid is a peptide with excitatory effect. N-Acetylglycyl-D-glutamic acid induces seizures in mice .

Cat. No.	Product Name	Type

HY-W127668

Triethylcholine iodide

Biochemical Assay Reagents

Triethylcholine iodide is a choline acetyltransferase inhibitor and a regulator of the acetylcholine synthesis pathway. Triethylcholine iodide inhibits acetylcholine synthesis in brain tissues and blocks neuromuscular and autonomic ganglionic transmission. Triethylcholine iodide exerts weak curare-like effects at extremely high concentrations. Triethylcholine iodide elevates the pentylenetetrazol seizure threshold, alters electroencephalogram patterns in Felis catus, but does not affect the maximal electroshock seizure threshold in Oryctolagus cuniculus. Triethylcholine iodide can be used in seizure-related research .

Cat. No.	Product Name	Target	Research Area

HY-P1237

C-Type Natriuretic Peptide (CNP) (1-22), human 2 Publications Verification	Histamine Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
C-Type Natriuretic Peptide (CNP) (1-22), human, a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor .

HY-138903

L-Homocysteic acid 1 Publications Verification L-HCA	iGluR	Neurological Disease
L-Homocysteic acid (L-HCA) is an endogenous excitatory amino acid that acts as a NMDA receptor agonist (EC₅₀: 14 μM). L-Homocysteic acid is neurotoxic, and can be used in the research of neurological disorders .

HY-P1237A

C-Type Natriuretic Peptide (CNP) (1-22), human TFA 2 Publications Verification	Histamine Receptor Endothelin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor .

HY-W023493

DL-Allylglycine 2-Aminopent-4-enoic acid	Amino Acid Decarboxylase	Neurological Disease
DL-Allylglycine (2-Aminopent-4-enoic acid) is a glutamate decarboxylase (GAD) inhibitor. DL-Allylglycine significantly increases mouse brain ornithine decarboxylase (ODC) activity and decreases S-adenosyl-L-methionine decarboxylase (SAM-DC) activity. DL-Allylglycine causes a marked decrease in brain GABA concentration. DL-Allylglycine has convulsant activity that can be used in studies to induce epileptic seizures .

HY-P2707

α-Dendrotoxin α-DTX	Sodium Channel Potassium Channel	Neurological Disease
α-Dendrotoxin (α-DTX) is a voltage-gated K ⁺ channel blocker and an acid-sensing ion channel (ASIC) inhibitor. α-Dendrotoxin blocks K_v1.1, K_v1.2, K_v1.6 and D-type (I_D) voltage-gated K ⁺ channels, and reversibly inhibits slowly inactivating potassium currents. α-Dendrotoxin induces epilepsy-related behaviors in mice. α-Dendrotoxin can be used in studies related to tonic-clonic seizures .

HY-P5183

Hm1a	Sodium Channel	Neurological Disease
Hm1a is a venom peptide and a selective hNaV1.1 activator with an EC₅₀ of 7.5 nM. Hm1a enhances hNaV1.1 and hNaV1.3 channel currents via delayed inactivation. Hm1a restores action potential firing in Dravet syndrome GABAergic inhibitory interneurons, reduces interictal epileptiform discharges and whole-brain hyperexcitability, lowers seizure frequency, and rescues premature death in Dravet syndrome mice. Hm1a can be used for the research of neurological disease, such as Dravet syndrome .

HY-W002299

Boc-D-Leucine monohydrate Boc-D-Leu-OH hydrate	Amino Acid Derivatives	Neurological Disease
Boc-D-Leucine monohydrate (Boc-D-Leu-OH hydrate) is an N-Boc-protected form of D-Leucine. D-Leucine is an unnatural isomer of L-Leucine that acts as an auto-inhibitor of lactic streptococci. D-Leucine shows potent anti-seizure effect .

HY-P1327

BVD 10	Neuropeptide Y Receptor	Neurological Disease
BVD 10, a neuropeptide Y (NPY) analogue peptide, is a highly selective NPY Y1 receptor antagonist. BVD10 significantly prevents NPY-induced glutamate increase. BVD 10 can be used for seizure research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2309

Kainic acid 30+ Cited Publications	Alkaloids Structural Classification other families Pyrrole Alkaloids Neurological Disease Classification of Application Fields Plants Disease Research Fields Biological Pesticide Research Source Classification Agricultural Research	EAAT
Kainic acid is a potent excitotoxic agent. Kainic acid hydrate also is an agonist for a subtype of ionotropic glutamate receptor. Kainic acid induces seizures .

HY-N0219

Bicuculline Maximum Cited Publications 37 Publications Verification (+)-Bicuculline	Alkaloids Lamprocapnos spectabilis (L.) Fukuhara Plants Isoquinoline Alkaloids Papaveraceae Source Classification	GABA Receptor
Bicuculline ((+)-Bicuculline) is A competing neurotransmitter GABA_A receptor antagonist (IC₅₀=2 μM). Bicuculline also blocks Ca ²⁺ activating potassium (SK) channels and subsequently blocks slow post-hyperpolarization (slow AHP). Bicuculline has anticonvulsant activity. Bicuculline can be used to induce seizures in mice .

HY-B0300

Penicillamine 3 Publications Verification D-(-)-Penicillamine	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Inflammation/Immunology Disease Research Fields Source Classification	Cuproptosis Drug Metabolite
Penicillamine (D-(-)-Penicillamine) is a penicillin metabolic degradation product, can be used as a heavy metal chelator. Penicillamine increases free copper and increases oxidative stress. Penicillamine has effect of seizures through nitric oxide/NMDA pathways. Penicillamine is a potential immune modulator. Penicillamine can be used for the research of Wilson disease, rheumatoid arthritis, and cystinuria .

HY-W010155

Tryptophol 2 Publications Verification Indole-3-ethanol	Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Apoptosis Caspase Bacterial
Tryptophol is an aromatic alcohol and secondary metabolite produced by microorganisms. Tryptophol induces apoptosis and cleavage of caspase-8. Tryptophol inhibits *Cunninghamella blakesleeana* biofilm. Tryptophol has anti-phage infection, biofilm formation regulation, anti-inflammatory, hemolytic, sleep induction, temperature change, seizure susceptibility and immune regulation activities. Tryptophol is used in the research of African trypanosomiasis, sleep disorders, epilepsy .

HY-N2522

Carboxyatractyloside dipotassium 2 Publications Verification Gummiferin dipotassium	other families Classification of Application Fields Terpenoids Other Diseases Diterpenoids Plants Disease Research Fields Source Classification	Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS)
Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca ²⁺ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .

HY-N1502

Carboxyatractyloside tripotassium 2 Publications Verification Gummiferin tripotassium	other families Classification of Application Fields Terpenoids Diterpenoids Plants Disease Research Fields Source Classification Cancer	Mitochondrial Metabolism Reactive Oxygen Species (ROS) Calcium Channel
Carboxyatractyloside tripotassium is a diterpenoid. Carboxyatractyloside tripotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside tripotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside tripotassium promotes ROS production, induces Ca ²⁺ release, and leads to mitochondrial dysfunction. Carboxyatractyloside tripotassium induces lethargy, weakness, and epileptic seizures in rats .

HY-B1302

Quinidine hydrochloride monohydrate 20+ Cited Publications	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Rubiaceae Cinchona calisaya Wedd. Plants Disease Research Fields Source Classification	P-glycoprotein PARP Caspase Apoptosis Potassium Channel
Quinidine hydrochloride monohydrate is an orally active antiarrhythmic agent. Quinidine hydrochloride monohydrate reduces the expression level of P-gp, inhibits P-gp-mediated efflux, increases the intracellular accumulation of P-gp substrates, induces PARP cleavage and Caspase-3 activation, and elevates the proportion of Apoptotic cells at the sub-G1 phase. Quinidine hydrochloride monohydrate exerts sustained block and open-channel block effects on I_K(f). Quinidine hydrochloride monohydrate alters the urinary metabolic ratio of Amphetamine, modulates the Pentylenetetrazol-induced seizure threshold, and regulates the anticonvulsant effect of Dextromethorphan. Quinidine hydrochloride monohydrate can be used in studies related to uterine sarcoma and seizures .

HY-N0660

Jujuboside B	Cardiovascular Disease Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .

HY-N0444

Rubiadin	Quinones Structural Classification Classification of Application Fields Anthraquinones Rubiaceae Phenols Polyphenols Plants Morinda officinalis How Inflammation/Immunology Disease Research Fields Source Classification	Reactive Oxygen Species (ROS)
Rubiadin is an orally active polyketide-derived compound and free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections .

HY-W008270

2(5H)-Furanone γ-Crotonolactone	Structural Classification Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Bacterial
2(5H)-Furanone (γ-Crotonolactone) is an endogenous metabolite. 2(5H)-Furanone mimics N-acyl homoserine lactone signals, occupies the binding site of LuxR homologs, and interferes with quorum sensing-mediated gene regulation. 2(5H)-Furanone inhibits quorum sensing mediated by AHLs with different acyl chain lengths. 2(5H)-Furanone inhibits biofilm formation of environmental Aeromonas hydrophila strains on polystyrene plates. 2(5H)-Furanone suppresses spike-and-wave discharges in a rat model of generalized absence seizures and exhibits selective activity against absence seizures. 2(5H)-Furanone can be used in studies related to bacteria infections and generalized absence seizures.

HY-Y0378

D-Leucine (R)-Leucine	Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite
D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-122489

DL-Laudanosine	Alkaloids Microorganisms Animals Isoquinoline Alkaloids Source Classification	Drug Metabolite
DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity .

HY-W010155R

Tryptophol (Standard) Indole-3-ethanol (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Apoptosis Caspase Bacterial
Tryptophol (Standard) (Indole-3-ethanol (Standard)) is an analytical standard of Tryptophol (HY-W010155). This product is intended for use in research and analytical applications.Tryptophol is an aromatic alcohol and secondary metabolite produced by microorganisms. Tryptophol induces Apoptosis and cleavage of caspase-8. Tryptophol inhibits *Cunninghamella blakesleeana* biofilm. Tryptophol has anti-phage infection, biofilm formation regulation, anti-inflammatory, hemolytic, sleep induction, temperature change, seizure susceptibility and immune regulation activities. Tryptophol is used in the research of African trypanosomiasis, sleep disorders, epilepsy.

HY-W013378R

Carbamazepine 10,11-epoxide (Standard)	Structural Classification Alkaloids Other Alkaloids Endogenous metabolite Source Classification	Reference Standards Drug Metabolite
Carbamazepine 10,11-epoxide (Standard) is the analytical standard of Carbamazepine 10,11-epoxide (HY-W013378). Carbamazepine 10,11-epoxide is a metabolite of Carbamazepine (HY-B0246). Carbamazepine 10,11-epoxide can be used to monitor for Carbamazepine .

HY-W415953

Periplanetin	Animals Saccharides Monosaccharides Source Classification	Sex Pheromone
Periplanetin is a peptide of the insect lipomotor hormone family (AKH family) that can be isolated from the secretion of the cervical organ of Periplaneta americana L. and Blatta orientalis L. The periplanetin peptide has potential analgesic activity and lowers the threshold of tonic seizures .

HY-W751152

α,β-Thujone	Terpenoids Artemisia austriaca Jacq. Plants Compositae Source Classification	GABA Receptor
α,β-Thujone is a component of the essential oils of some plants. α,β-Thujone causes cancers in male rats and induces seizures in the highest doses .

HY-122489A

(S)-Laudanosine	Alkaloids Microorganisms Isoquinoline Alkaloids Source Classification	Opioid Receptor GABA Receptor
(S)-Laudanosine is an alkaloid that can be found in poppies and is the S-enantiomer of Laudanosine. Laudanosine acts on the central nervous system and cardiovascular system, inhibiting low-affinity GABA receptors with an IC₅₀ value of 10 μM, and can cause seizures, hypotension, and bradycardia. Additionally, Laudanosine exerts analgesic effects by competitively binding to the opioid Mu-1 receptor (K_i = 2.7 μM) .

HY-N0219R

Bicuculline (Standard) (+)-Bicuculline (Standard)	Alkaloids Structural Classification Lamprocapnos spectabilis (L.) Fukuhara Plants Isoquinoline Alkaloids Papaveraceae Source Classification	Reference Standards GABA Receptor
Bicuculline (Standard) is the analytical standard of Bicuculline. This product is intended for research and analytical applications. Bicuculline ((+)-Bicuculline) is A competing neurotransmitter GABAA receptor antagonist (IC₅₀=2 μM). Bicuculline also blocks Ca2+ activating potassium (SK) channels and subsequently blocks slow post-hyperpolarization (slow AHP). Bicuculline has anticonvulsant activity. Bicuculline can be used to induce seizures in mice .

HY-W751152R

α,β-Thujone (Standard)	Terpenoids Artemisia austriaca Jacq. Plants Compositae Source Classification	Others Reference Standards
α,β-Thujone (Standard) is the analytical standard of α,β-Thujone. This product is intended for research and analytical applications. α,β-Thujone is a component of the essential oils of some plants. α,β-Thujone causes cancers in male rats and induces seizures in the highest doses .

HY-N2522R

Carboxyatractyloside dipotassium (Standard) Gummiferin dipotassium (Standard)	other families Terpenoids Diterpenoids Plants Source Classification	Reference Standards Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS)
Carboxyatractyloside (dipotassium) (Standard) is the analytical standard of Carboxyatractyloside dipotassium (HY-N2522). This product is intended for research and analytical applications. Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca ²⁺ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .

HY-B0300R

Penicillamine (Standard) D-(-)-Penicillamine (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source Classification	Cuproptosis Reference Standards Drug Metabolite
Penicillamine (Standard) is the analytical standard of Penicillamine. This product is intended for research and analytical applications. Penicillamine (D-(-)-Penicillamine) is a penicillin metabolic degradation product, can be used as a heavy metal chelator. Penicillamine increases free copper and increases oxidative stress. Penicillamine has effect of seizures through nitric oxide/NMDA pathways. Penicillamine is a potential immune modulator. Penicillamine can be used for the research of Wilson disease, rheumatoid arthritis, and cystinuria .

HY-122489R

DL-Laudanosine (Standard)	Alkaloids Structural Classification Microorganisms Animals Isoquinoline Alkaloids Source Classification	Reference Standards Drug Metabolite
DL-Laudanosine (Standard) is the analytical standard of DL-Laudanosine. This product is intended for research and analytical applications. DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity .

HY-W008270R

2(5H)-Furanone (Standard) γ-Crotonolactone (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
2(5H)-Furanone (Standard) is the analytical standard of 2(5H)-Furanone. This product is intended for research and analytical applications. 2(5H)-Furanone (γ-Crotonolactone) is an endogenous metabolite. 2(5H)-Furanone mimics N-acyl homoserine lactone signals, occupies the binding site of LuxR homologs, and interferes with quorum sensing-mediated gene regulation. 2(5H)-Furanone inhibits quorum sensing mediated by AHLs with different acyl chain lengths. 2(5H)-Furanone inhibits biofilm formation of environmental Aeromonas hydrophila strains on polystyrene plates. 2(5H)-Furanone suppresses spike-and-wave discharges in a rat model of generalized absence seizures and exhibits selective activity against absence seizures. 2(5H)-Furanone can be used in studies related to bacteria infections and generalized absence seizures.

HY-N18014

Naringenin 4',7-dimethyl ether	Structural Classification Flavonoids Pistacia chinensis Bunge Flavonones Plants Anacardiaceae Source Classification	Drug Derivative
Naringenin 4',7-dimethyl ether, Naringenin (HY-N0100) derivative is an anti-seizure agent. Naringenin 4',7-dimethyl ether attenuates pentylenetetrazole-induced seizures in larval zebrafish and reduces seizures in the mouse 6-Hz psychomotor seizure model. Naringenin 4',7-dimethyl ether can be used for the research of epilepsy .

HY-Y0378R

D-Leucine (Standard) (R)-Leucine (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
D-Leucine (Standard) is the analytical standard of D-Leucine. This product is intended for research and analytical applications. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-N9749

Qingyangshengenin 3-O-β-D-cymaropyranosyl-(1→4)-β-D-digitoxopyranoside	Apocynaceae Structural Classification Cynanchum otophyllum C. K. Schneid. Plants Steroids Source Classification	Drug Derivative
Qingyangshengenin 3-O-β-D-cymaropyranosyl-(1→4)-β-D-digitoxopyranoside is a natural steroid.

HY-N0660R

Jujuboside B (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards ERK p38 MAPK Akt PI3K 11β-HSD STING VEGFR Ferroptosis Autophagy Apoptosis Keap1-Nrf2 Caspase PARP AMPK
Jujuboside B (Standard) is the analytical standard of Jujuboside B. This product is intended for research and analytical applications. Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.

Cat. No.	Product Name	Chemical Structure

HY-Y0378S

D-Leucine-d10
D-Leucine-d₁₀ is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-W750342

Tryptophol-d4

Tryptophol-d₄ (Indole-3-ethanol-d₄) is the deuterium labeled Tryptophol (HY-W010155). Tryptophol is an aromatic alcohol and secondary metabolite produced by microorganisms. Tryptophol induces apoptosis and cleavage of caspase-8. Tryptophol inhibits Cunninghamella blakesleeana biofilm. Tryptophol has anti-phage infection, biofilm formation regulation, anti-inflammatory, hemolytic, sleep induction, temperature change, seizure susceptibility and immune regulation activities. Tryptophol is used in the research of African trypanosomiasis, sleep disorders, epilepsy .

HY-B0495S4

Lamotrigine-13C3
Lamotrigine- ¹³C₃ is the ¹³C-labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .

HY-114703S1

Eslicarbazepine-d4
Eslicarbazepine-d₄ (BIA 2-194-d₄) is deuterium labeled Eslicarbazepine. Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.

HY-B0124S

Zonisamide-d4
Zonisamide-d₄ is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with K_is of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease .

HY-B0495S5

Lamotrigine-d3
Lamotrigine-d₃ is the deuterium labeled Lamotrigine . Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .

HY-B0495S3

Lamotrigine-13C2,15N
Lamotrigine- ¹³C₂, ¹⁵N is the ¹³C and ¹⁵N labeled Lamotrigine . Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .

HY-W013378S

Carbamazepine 10,11 epoxide-d2
Carbamazepine 10,11 epoxide-d₂ is the deuterium labeled Carbamazepine 10,11 epoxide . Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .

HY-B0495S1

Lamotrigine-13C,d3
Lamotrigine- ¹³C,d₃ is the ¹³C- and deuterium labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy,?focal seizure, et al .

HY-B0495S6

Lamotrigine-13C2,15N2,d3

Lamotrigine- ¹³C₂, ¹⁵N₂,d₃ is ¹⁵N and deuterated labeled Lamotrigine (HY-B0495). Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na ⁺ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .

HY-114703S

Eslicarbazepine-d3
Eslicarbazepine-d₃ (BIA 2-194-d₃) is the deuterium labeled Eslicarbazepine (HY-114703). Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.

HY-B0495S7

Lamotrigine-13C
Lamotrigine- ¹³C (LTG- ¹³C) is ¹³C labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na ⁺ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy,?focal seizure, et al .

HY-W012481S

Nirvanol-d5
Nirvanol-d₅ (Ethylphenylhydantoin-d₅) is deuterium labeled Nirvanol (HY-W012481) . Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .

HY-B0495S

Lamotrigine-13C3,d3
Lamotrigine- ¹³C₃,d₃ is the ¹³C-labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy,?focal seizure, et al .

HY-B0495S8

Lamotrigine-13C7,15N

Lamotrigine- ¹³C₇, ¹⁵N (LTG- ¹³C₇, ¹⁵N) is ¹³C and ¹⁵N labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na ⁺ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy,?focal seizure, et al .

HY-W013378S2

Carbamazepine 10,11-epoxide-13C,d2
Carbamazepine 10,11-epoxide- ¹³C,d₂ is the deuterium labeled Carbamazepine 10,11-epoxide-C13. Carbamazepine 10,11-epoxide-C13 is a ¹³C-labled Carbamazepine 10,11-epoxide. Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .

HY-B0124S2

Zonisamide-13C6

Zonisamide- ¹³C₆ (AD 810- ¹³C₆) is ¹³C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-B0696S

Tiagabine-d6

Tiagabine-d₆ (NO050328-d₆) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .

HY-B0696AS

Tiagabine-d4 hydrochloride

Tiagabine-d₄ hydrochloride is deuterated labeled Tiagabine hydrochloride (HY-B0696A). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .

HY-B0124S3

Zonisamide-15N,d4

Zonisamide- ¹⁵N,d₄ is the ¹⁵N- and deuterium labeled Zonisamide (HY-B0124). Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-158252S

Tiagabine-d5 hydrochloride

Tiagabine-d₅ (hydrochloride) is deuterium labeled Tiagabine (hydrochloride). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .

HY-B0696S1

Tiagabine-d4

Tiagabine-d₄ (NO050328-d₄) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .

Cat. No.	Product Name		Classification

HY-148410A

Zorevunersen sodium STK-001 sodium		Antisense Oligonucleotides
Zorevunersen sodium is an antisense oligonucleotide targeting the Scn1a gene based on TANGO technology. Zorevunersen sodium increases Scn1a mRNA transcripts and elevates the expression level of NaV1.1 protein. Zorevunersen sodium restores the excitability of PV interneurons, thereby reducing seizures and prolonging survival in mice. Zorevunersen sodium can be used for research on Dravet syndrome .

HY-148410

Zorevunersen STK-001		Antisense Oligonucleotides
Zorevunersen is an antisense oligonucleotide targeting the Scn1a gene based on TANGO technology. Zorevunersen increases Scn1a mRNA transcripts and elevates the expression level of NaV1.1 protein. Zorevunersen restores the excitability of PV interneurons, thereby reducing seizures and prolonging survival in mice. Zorevunersen can be used for research on Dravet syndrome .

HY-103185A

CCPA hemihydrate 2-Chloro-N6-cyclopentyladenosine hemihydrate		Nucleoside Analogs
CCPA (2-Chloro-N6-cyclopentyladenosine) hemihydrate a highly selective A1 adenosine receptors agonist with a K_i of 0.4 nM. CCPA hemihydrate inhibits adenylate cyclase with an IC₅₀ of 33 nM. CCPA hemihydrate exhibits anti-seizure and cardiacprotective activity. CCPA hemihydrate can be used for the research of seizure and myocardial infarction .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Seizures

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products